Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Longeveron’s phase 2b stem cell flop spurs cost cutting, exploration of ‘all options’

Longeveron’s phase 2b stem cell flop spurs cost cutting, exploration of ‘all options’

  • September 17, 2026

A phase 2b study of Longeveron’s stem cell therapy in a pediatric heart disease has missed its primary endpoint, prompting the cash-strapped biotech to “review all options” for the business.

Leave A Comment

Fields (*) Mark are Required